Cas No.: | 848354-66-5 |
Synonyms: | NCH-51 |
SMILES: | C(SCCCCCCC(=O)NC1=NC(C2=CC=CC=C2)=CS1)(=O)C(C)C |
Formula: | C20H26N2O2S2 |
M.Wt: | 390.56 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM. |
Target: | IC50 value: 1-10 μM (EC50) Target: HDAC |
In Vitro: | In cancer cell growth inhibition assay, PTACH shows strong activity. PTACH inhibits various cancer cells with EC50 of 2.3, 9.1, 3.0, 2.6, 1.1, 4.5, 2.4, 5.0, and 4.5 μM for MDA-MB-231 breast cancer, SNB-78 central nervous system, HCT116 colon cancer, NCI-H226 lung cancer, LOX-IMVI melanoma, SK-OV-3 ovarian cancer, RXF-631L renal cancer, St-4 stomach cancer, and DU-145 prostate cancer. |
References: | [1]. Suzuki T, et al. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-1032. |